cytokine secretion by MCL cells. We demonstrated that MCL-secreted IL-10 inhibits CD1d-mediated antigen presentation and pre-treatment with TSA abrogates secretion of IL-10 by MCL. Taken together, our studies demonstrate the efficacy of HDACi in restoring anti-tumor responses to MCL through both cell-intrinsic and cell-extrinsic mechanisms and strongly implicate a role for HDACi in enhancing immune responses to cancer.
Introduction
A hallmark of cancer cell survival is their ability to evade immune destruction [1, 2] . This is essential for the tumor because the host immune system possesses the potential to eliminate malignancies through a multilayered process that includes early recognition of transformation events by mediators of innate immunity, followed by the development of a strong and highly specific adaptive immune response [3] . Natural killer T (NKT) cells are a unique subset of T cells that recognize glycolipid antigens in the context of CD1d, a non-classical MHC class I-like molecule [4] [5] [6] . NKT cells have the capacity to mount strong anti-tumor responses and have thus become a major focus in the development of effective cancer immunotherapy [7] [8] [9] . In this respect, NKT cells have been shown to augment anti-tumor responses due, in part, to their capacity to rapidly produce large amounts of IFN-γ, which acts on NK cells to target MHC-negative tumors, and, also, to promote CD8 cytotoxic T cell-mediated killing of MHC-positive tumors [7, 8] .
Given the importance of NKT cells in anti-tumor immunity, studies elucidating the mechanisms of tumor escape from NKT cell-mediated anti-tumor immunity are crucial. NKT cells have a well-established role in mediating antitumor responses [5, 10] . However, studies from our laboratory and others have shown that NKT cells are physically and functionally reduced in cancer patients [11] [12] [13] , which suggests that tumors may utilize various mechanisms to evade NKT cell-mediated immune surveillance. Specifically, we posit that lymphomas utilize epigenetic mechanisms to rapidly undergo immunologic sculpting, allowing poorly immunogenic clones to survive. In light of data demonstrating that tumors dysregulate antigen presentation to escape anti-tumor immune responses [14] [15] [16] [17] , the focus of our studies is on epigenetic modulation of CD1d-mediated antigen presentation and mechanisms of tumor escape from NKT cell-mediated immune surveillance.
MCL presents a unique target for immunotherapy [18] [19] [20] . Although previously thought to be a homogeneous disease, the heterogeneity of MCL is now better understood, with many pathways discovered to be of prognostic value [19] . However, the mechanisms by which these pathways contribute to MCL pathogenesis are not well understood. For example, Signal Transducer and Activator of Transcription 3 (STAT3) is constitutively activated in MCL [21, 22] . Importantly, although STAT3 has been shown to be upregulated in MCL, as well as many other cancers [23] , and to contribute to tumor progression and tumor immune evasion [24] , the exact mechanisms are not well understood [25] .
HDACs are a family of enzymes that regulate diverse cellular events such as gene expression, cell proliferation, and immune pathways through deacetylation of their protein targets [26, 27] . Moreover, HDAC activities are frequently dysregulated in cancer and have been implicated not only in tumor onset, but also tumor progression [26, 27] . Recent evidence demonstrates that HDACs facilitate tumor evasion from immune surveillance and HDAC inhibitors (HDACi) have thus garnered attention as a potential therapy in a variety of cancers [26, 28, 29] . HDACs possess many non-canonical targets, such as the mediator of inflammation STAT3 [30, 31] . Given the well-established role of inflammation in tumor progression [32] , we investigated the cell-intrinsic and cell-extrinsic mechanisms by which treatment with HDACi regulates CD1d-mediated antigen presentation to NKT cells.
Materials and methods

Cell lines
The NKT cell hybridoma cell lines DN32.D3, N38-3C3, and N37-1A12 have been previously described [8, 33, 34] . The cells were cultured in IMDM medium supplemented with 5 % FBS, 2 mM l-glutamine, and penicillin/streptomycin. LCD1dwt cells are CD1d1-transfected mouse fibroblast cells, which were kindly provided by Dr. Randy Brutkiewicz (Indiana University School of Medicine, Indianapolis, IN, USA). The LCD1dwt cells were cultured in DMEM supplemented with 10 % FBS, 2 mM l-glutamine, 500 μg/mL G418 as a selection agent, and penicillin/streptomycin. DR4-restricted 17.9 CD4
+ T cell hybridomas were generously provided by Dr. Janice Blum (Indiana University School of Medicine, Indianapolis, IN, USA) and cultured in RPMI supplemented with 10 % FBS, 50 μM 2-mercaptoethanol, and 2 mM l-glutamine. Mantle cell lymphoma lines, JeKo-1 and SP53, were graciously provided by Dr. Raymond Lai (University of Alberta, Edmonton, AB, Canada). The cell lines were authenticated by assessing expression of cell surface markers, such as CD19, CD20, kappa, and lambda, as described [35] . JeKo-1 and SP53 were cultured in RPMI 1640 medium supplemented with nonessential amino acids (Sigma-Aldrich, St. Louis, MO, USA), sodium pyruvate (Gibco, Carlsbad, CA, USA), 2-mercaptoethanol (Gibco), vitamin solution (Gibco), 10 % fetal bovine serum (Gibco), and penicillin/streptomycin (Gibco).
Peripheral blood mononuclear cells (PBMCs) and primary NKT cells
Buffy coats were purchased from the New York Blood Bank (New York City, NY, USA), and PBMCs were isolated via centrifugation in SepMate tubes (Stem Cell Technologies, Vancouver, BC, Canada) containing Ficoll-Paque (GE Healthcare, Uppsala, Sweden). NKT were isolated and expanded as previously described [36] . Primary NKT cells were cultured and tested for functionality as previously described [36] .
NKT cell assays
To measure NKT cell responses to lymphoma cells, MCL cells were treated with the indicated amounts of drugs for 4 h, pulsed with α-GalCer (100 ng/mL), washed extensively, and co-cultured (1 × 10 5 cells/well) with primary human NKT cells (2 × 10 4 cells/well) in triplicate in 96-well microtiter plates. In assays using NKT cell hybridomas, MCL cells were pre-treated with drugs for 4 h, pulsed with α-GalCer (100 ng/mL), fixed in 0.05 % paraformaldehyde for 20 min, washed extensively, and cocultured (5 × 10 5 cells/well) with the NKT cell hybridomas (5 × 10 4 cells/well) in triplicate in 96-well microtiter plates. In human NKT cell assays, after a 42-to 72-h coculture, supernatants were harvested, and IFN-γ was measured by ELISA kit purchased from BioLegend (San Diego, California, USA). In NKT cell hybridoma assays, after 16-to 24-h co-culture, supernatants were harvested and IL-2 was measured by standard ELISA kit (BD Biosciences, San Jose, CA, USA).
RT-PCR
JeKo-1 and SP53 were treated with 1 µM TSA for 0-4 h, and mRNA was isolated from the cells using standard TRIzol reagent. cDNA was made using Bio-Rad iScript kit (Hercules, CA, USA). PCR was performed using CD1D primers designed with the help of Primer-BLAST Web site (NIH). 18S primers were used as a loading/positive control. Following amplification, the products were resolved on 1.5 % agarose gels and images were captured using Syngene G:Box imaging module and GeneSnap software. Densitometry analyses were made using ImageJ software.
Western blotting
Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich), supplemented with phenylmethylsulfonyl fluoride (PMSF) (Cell Signaling Technology, Beverly, MA, USA). Proteins were resolved by electrophoresis on a 4-12 % gradient polyacrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane using the Bolt Mini Blot Module (Life Technologies, Carlsbad, CA, USA). All polyacrylamide gels, gel boxes, Bolt Mini transfer modules, buffers, and other materials were purchased from Life Technologies and were used according to the manufacturer's instructions. Membranes were probed with antibodies to HDACs 1-3, clones 10E2, 3F3, and 7G6C5, respectively, purchased from Cell Signaling Technology. GAPDH levels were assessed on the same blot as the test protein using an antibody (clone 14C10) from Cell Signaling Technology. STAT3 (clone 79D7) and phospho-STAT3 (Y705, clone D3A7) antibodies were purchased from Cell Signaling Technology. DyLight800-conjugated anti-rabbit secondary antibody was purchased from Thermo Scientific (Waltham, MA, USA), and DyLight800-conjugated anti-mouse antibody was purchased from Cell Signaling Technology. Membranes were scanned using the Odyssey Imaging System from Li-COR Biosciences (Lincoln, NE, USA).
Immunoprecipitation
STAT3 was immunoprecipitated from JeKo-1 lysates using Protein G PLUS-Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA), following the manufacturer's instructions. Immunoprecipitation was performed with three STAT3 antibodies: D3Z2G (Cell Signaling Technology), 79D7 (Cell Signaling Technology), and C-20 (Santa Cruz). Immunoprecipitates were resolved by SDS-PAGE, and HDAC2 detection was performed as described above.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed by Active Motif (Carlsbad, CA, USA), with a validated and tailored protocol. Promoter probes were designed by Active Motif to span the known sequence of the CD1D promoter [37] and included appropriate positive controls: beta-actin (ACTB) and interferon response factor 1 (IRF1). Untr12 is the negative control, comprising a sequence from a gene desert on chromosome 12, to which no transcription factors are expected to bind. Positive signal was defined as at least twofold enrichment over Untr12.
Knockdown of HDAC2
HDAC2 knockdown was achieved using lentiviral particles purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), at multiplicity of infection (MOI) of 2. Polybrene-based transduction was carried out according to the manufacturer's instructions. Stable transductants were cultured in medium containing the selection agent puromycin dihydrocholoride at a final concentration of 2.5 μg/mL (ready-made solution was purchased from Sigma-Aldrich, St. Louis, MO, USA). HDAC2 knockdown was confirmed by Western blotting.
Antigens and inhibitors
α-Galactosylceramide was purchased from Enzo Life Sciences (New York City, NY, USA) and used at a final concentration of 100 ng/mL. Human serum albumin was purchased from Sigma-Aldrich and used at 10 μM final concentration. Trichostatin-A was purchased from Cell Signaling Technology and reconstituted in ethanol. MC1568 (Sigma-Aldrich) was reconstituted in DMSO. Panobinostat/LBH589 (Biovision (Milpitas, CA, USA)) was reconstituted in DMSO.
Flow cytometry
Cells were stained in PBS containing 0.5 % bovine serum albumin and 2 mM EDTA for 30 min at 4 °C with a PEconjugated antibody to human CD1d (clone 51.1) and APC-conjugated antibody to human DR4 (clone L243) from BioLegend. Detection of mouse CD1d was accomplished using PE-conjugated antibody to murine CD1d (clone 1B1) from eBioscience. Intracellular cytokine staining was accomplished using PE-conjugated antibodies for STAT3 (clone M59-50) and phospho-STAT3 (pY705, clone 4/P-STAT3) from BD Biosciences, following the standard protocol by BD Biosciences. Multiplex assay for inflammatory cytokines was performed using LEGENDplex Human Inflammation Panel from BioLegend, following kit instructions. Data were collected on an LSR II from BD Biosciences and analyzed using FCS Express Version 5 from De Novo Software (Los Angeles, CA, USA). Geometric means of histograms were reported according to the calculations performed by the FCS Expression Version 5 software.
Statistical analyses
All experiments were performed at least three times. Student's t tests were performed to test for significant differences. A p value of <0.05 was considered significant. All analyses were performed using GraphPad Prism software (La Jolla, CA, USA). * p < 0.05, ** p < 0.005, and *** p < 0.0001.
Results
HDACi treatment enhances CD1d-mediated antigen presentation
To examine the effects of HDACi on CD1d-mediated antigen presentation, LCD1d cells were pre-treated with Trichostatin-A (TSA) for 4 h, washed extensively, and cocultured with NKT cell hybridomas, DN32.D3, N38-3C3, and N37-1A12. CD1d-mediated antigen presentation was enhanced (Fig. 1a, b) . Similarly, we assessed MHC class II-mediated antigen presentation by co-culturing vehicleand TSA-treated LCD1d cells expressing DR4 with DR4-specific T cell line, 17.9. MHC class II-mediated antigen presentation was enhanced (Fig. 1c) . Next, we sought to determine whether TSA treatment enhances CD1d-mediated antigen presentation by MCL cells. Thus, we pre-treated two MCL cell lines, JeKo-1 and SP53, with TSA for 4 h and co-cultured the cells with DN32.D3 and and SP53 were treated with TSA, pulsed with α-GalCer (100 ng/mL), and co-cultured with primary human NKT cells derived from healthy donor blood. e, f Similar experiments were performed with primary human NKT cells; percent control IFN-γ production is shown for a representative experiment. *p < 0.05, **p < 0.005, and ***p < .0001 primary human NKT cells expanded from healthy donor blood ( Fig. 1d-f ). We found that TSA treatment enhances CD1d-mediated antigen presentation by MCL cells. The table presented in Supp. Figure 1c summarizes the effects of the panel of HDACi tested. We tested HDACi that inhibit both class I and class II HDACs (TSA and LBH589) and only class II HDACs (MC1568) (Supp. Figure 1) . TSA is the prototypical HDACi, and it induced both CD1d and MHC class II-mediated antigen presentation; therefore, we used TSA to ascertain the mechanisms by which HDACi enhance antigen presentation.
HDACi treatment induced CD1D mRNA and cell surface protein levels
We sought to determine whether the increase in CD1d-mediated NKT cell activation following treatment with TSA was due to an increase in CD1d expression. In good agreement with Yang et al. [38] , who demonstrated that TSA treatment results in an increase in CD1D mRNA levels, we found that CD1D mRNA is induced rapidly following TSA treatment (Fig. 2a) . Interestingly, the rapid increase in CD1D mRNA followed by a slight decline in the mRNA is consistent with epigenetic changes, which are rapid and reversible. In addition, TSA treatment induced an increase in cell surface CD1d expression, as assessed by flow cytometry (Fig. 2b, d , and e). However, TSA treatment did not alter MHC class II cell surface expression, as assessed by flow cytometry, suggesting that TSA may differentially regulate CD1d-and MHC class II-mediated antigen processing and presentation through recruitment of different HDACs to the CD1D and MHC class II promoters, or through regulation of antigen processing pathways. Moreover, different HDACs may be involved in regulating CD1d-and MHC class II-mediated antigen presentation.
HDAC2 binds the CD1D promoter and is the main HDAC regulating CD1D transcription in MCL
To identify which specific HDAC(s) are involved in CD1d-mediated antigen presentation, we examined HDAC expression in vehicle-and TSA-treated JeKo-1 and SP53 cells by Western blotting. We found that TSA treatment inhibited HDACs 1 and 2, without significantly affecting HDAC3 levels (Fig. 3a) . Chromatin immunoprecipitation (ChIP) identified HDAC2 as binding at the CD1D promoter, at both proximal and distal regions, whereas HDACs 1 and 3 did not bind (Fig. 3b) . Beta-actin (ACTB) served as a positive control for HDAC binding. The primers spanned the known proximal (+42) and distal (−498) regions of the CD1D promoter. Thus, we knocked down HDAC2 in JeKo-1 and assessed antigen presentation. HDAC2 knockdown ( Supplementary Fig. 1a ) enhanced antigen presentation to both NKT hybridomas and primary human NKT cells (Fig. 3c, d) . Importantly, treatment of shHDAC2 JeKo-1 cells with TSA did not further induce CD1d-mediated antigen presentation (Fig. 3e ). These data demonstrate that inhibition of HDAC2 is the main mechanism by which TSA treatment enhances CD1d-mediated antigen presentation by MCL. Notably, CD1d levels were similar in TSAtreated JeKo-1 control and shHDAC2 cells (Fig. 3f) . These data suggest that HDAC2 is the main HDAC regulating CD1d-mediated antigen presentation. To confirm a role for HDAC2 in regulating CD1d cell surface expression and to demonstrate that minute changes in CD1d expression can have a profound effect on NKT cell responses, we selected shHDAC2 clones expressing relatively high and low levels of CD1d (termed low and high clones). We confirmed HDAC2 knockdown in the clones and assessed CD1d surface expression by flow cytometry (Fig. 4a, b) . Next, we assessed their antigen presentation capabilities by co-culturing the clones with NKT cell hybridomas (Fig. 4c) and primary human NKT cells (Fig. 4d) . Importantly, we noted a dose-dependent relationship in CD1d levels and the ability of the JeKo-1 shHDAC2 clones to activate NKT cells. Specifically, the clone expressing higher CD1d levels displayed enhanced antigen presentation capabilities, compared to the clone expressing lower levels of CD1d. Thus, downregulation of CD1d levels via HDAC upregulation may serve as a mechanism by which tumors evade recognition by NKT cells. Notably, we showed that NKT cells are sensitive to minute changes in CD1d levels.
HDAC2 regulates STAT3 and thus alters STAT3-inducible cytokine secretion
Given that TSA treatment induced CD1D transcription, we sought to identify transcription factors regulated by HDACs and immunoprecipitated STAT3, which we found to be in a complex with HDAC2 (Fig. 5a ). However, we found that STAT3 does not bind to the CD1D promoter at the distal (−498) and proximal (+42) regions, as assessed by ChIP, with interferon response factor 1 (IRF1) serving as a positive control (Fig. 5b) . Given that STAT3 levels can be modulated by HDACi treatment [22, 39] , we hypothesized that TSA inhibits STAT3 in MCL and examined the effects of TSA on STAT3 expression. Following TSA treatment, both phosphorylated and total STAT3 were inhibited (Supplementary Fig. 2b ). Thus, we sought to determine whether HDACi treatment inhibits secretion of STAT3-regulated inflammatory cytokines. We utilized a multiplex flow cytometric bead-based array to assess the levels of various inflammatory cytokines in the supernatants of vehicle-and TSA-treated JeKo-1 and SP53 cells. We found that TSA treatment inhibited secretion of MCP-1, IL-8, and IL-10 ( Fig. 5c ). We confirmed TSA-mediated inhibition of IL-10 by ELISA (Fig. 5d) , with phorbol 12-myristate 13-acetate and ionomycin (P/I) serving as a positive control. We found that both JeKo-1 and SP53 secrete IL-10, even in the absence of stimulation, and that TSA treatment inhibits IL-10 secretion (Fig. 5d) . Given the multitude of cytokines secreted by MCL cells, we chose to focus on a cytokine-IL-10-that has been previously shown to negatively regulate antigen presentation [40] . Furthermore, we set up an LCD1d-based in vitro system using purified cytokines in order to eliminate confounding variables, such as the effects of other cytokines and inhibitory lipids that are produced by MCL cells. To elucidate the effects of IL-10 on antigen presentation, LCD1d cells were treated with purified recombinant IL-10 and cultured with NKT cell hybridomas. IL-10 pre-treatment suppressed CD1d-mediated antigen presentation to NKT cell hybridomas, DN32.D3 and N38-3C3. We confirmed that IL-10 activates STAT3 by performing a Western blot for STAT3 and phospho-STAT3 ( Supplementary Fig. 2c ). Overall, these studies demonstrate that HDAC2 regulates STAT3, which in turn modulates inflammatory cytokine secretion, which can suppress CD1d-mediated antigen presentation. Moreover, we demonstrated that treatment with HDACi resulted in a concomitant increase in CD1d cell surface expression and decrease in IL-10 production, thus increasing tumor cell immunogenicity (Fig. 6 ).
Discussion
HDACs exert their effects via modulation of numerous processes within the mammalian cell: They regulate cell processes of both healthy and cancerous cells, such as cell cycle progression and proliferation. Furthermore, they have important immunomodulatory roles, achieved through the alteration of cytokine profiles of immune cells [41] and differential gene expression. While other groups have ascribed a role for HDACs in regulating CD1D transcription [38, 42] , our study is the first to demonstrate that HDACi have a functional effect and enhance CD1d-mediated antigen presentation. In our studies, we tested the hypothesis that tumors use epigenetic mechanisms to dysregulate CD1d-mediated antigen presentation. We examined CD1d-mediated antigen presentation to NKT cells following treatment with HDACi. Consistent with previous studies [43] [44] [45] , we found that treatment with TSA, a pan-HDACi, enhanced both CD1d and MHC class II-mediated antigen presentation. Furthermore, we assessed CD1d and MHC class II levels following TSA treatment and found that CD1d levels were induced, but MHC class II levels were unaffected, suggesting that different mechanisms are responsible for the functional effects.
While our studies suggest that HDACi positively impact antigen presentation, HDACi have been shown to inhibit antigen presentation by professional antigen-presenting cells. HDACi can suppress the expression of costimulatory molecules on dendritic cells (DCs), change their metabolism as well as their cytokine profiles, and can impair their antigen uptake capabilities [46] . Specifically, valproic acid and LBH589 have been shown to reduce the expression of costimulatory molecules CD80, CD40, and CD83 and alter expression of adhesion molecules [46, 47] . As a result of these changes, both MHC class I-and class II-mediated antigen-specific immune responses relayed by DCs were impaired, limiting their ability to activate T cells and NKT cells [48] . The discrepancies in the effects of HDACi may be attributed to the fact that HDACs have normal functions, but due to their overexpression and aberrant recruitment in tumors, HDACi treatment of tumors restores the "normal" epigenomic program by fine-tuning HDAC activities. Thus, future studies are needed to determine cell-specific effects of HDACi on antigen presentation.
We found that HDACi enhance antigen presentation due, at least in part, to a dose-dependent rapid increase in CD1D mRNA and, subsequently, CD1d cell surface expression. Finally, treatment with HDACi resulted in a decrease in STAT3 as well as STAT3-inducible cytokine secretion by MCL. We found that HDAC2 binds to the CD1D promoter. However, we found that STAT3 did not bind to the CD1D promoter. There are several explanations for this finding. First, it is possible that STAT3 regulates CD1D gene expression through binding at distant enhancer regions. Future studies will determine whether STAT3 regulates CD1D gene expression through binding at distal enhancers or whether it binds at the promoter of a gene whose products regulates CD1D gene expression. Moreover, it is possible that STAT3 binds the CD1D promoter indirectly. For example, one study determined that, in a panel of lymphoma cell lines, STAT3 binds the GADD45G promoter indirectly, through association with NF-κB and that panobinostat inhibits the binding of the NF-κB-STAT3 complex [49] .
It is possible that STAT3 plays a positive role in CD1d-mediated antigen presentation. Iyer et al. [50] demonstrated that STAT3 inhibition reduced endogenous lipid antigen presentation to NKT cells. Knockdown of STAT3 led to decreased levels of uridine diphosphate (UDP) glucose ceramide glucosyltransferase, an enzyme involved in glycosphingolipid biosynthesis [50] . Moreover, CD1d levels of HEK-293 cells containing STAT3 knockdown were not deemed significantly different [50] . However, it must be noted these studies used CD1d transfectants; thus, CD1d was not regulated by its natural, endogenous promoter. In contrast, our studies focused on CD1d regulation in lymphoma cells. The same signaling pathway can have different outcomes in fibroblasts, compared to cancer cells, due to cross talk with other pathways that are uniquely upregulated in cancer. Thus, although STAT3 has been shown to enhance endogenous lipid antigen presentation through modulation of glycosphingolipid biosynthesis pathways, future studies are needed to delineate the cell-specific effects of STAT3 signaling. Moreover, future studies are needed to determine whether STAT3 is aberrantly recruited to the CD1D promoter in tumors, which would provide a rational explanation for discrepant findings in different systems.
Here, we present data that provide evidence that HDACi may be combined with NKT cell-based immunotherapy. Importantly, we demonstrate that treatment with HDACi not only induces CD1d-mediated antigen presentation, but also inhibits inflammatory cytokine secretion, which may contribute to suppression of anti-tumor NKT cell responses. Our studies demonstrate the efficacy of HDACi in restoring anti-tumor responses to MCL through both cell-intrinsic and cell-extrinsic mechanisms. Collectively, these results suggest that HDACi may work to enhance the immune response by increasing antigen processing and presentation, while inhibiting inflammatory cytokine secretion. While various combinations of HDACi with other chemotherapeutic agents have been widely studied, the combination of HDACi with immunotherapy is a novel avenue, with mechanistic studies helping to build the foundation for the application of this combination in the clinic [51] .
